Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17371192 | 1.00 | L3MBTL1 (0.35) | L3MBTL1ZDHHC7ABCB1CA1CA2 | |
| SCHEMBL17371226 | 0.84 | L3MBTL1 (0.33) | L3MBTL1ZDHHC7ABCB1CA1CA2 | |
| SCHEMBL17371225 | 0.81 | CA1 (0.38) | CA1KDM4EATM | |
| SCHEMBL17371224 | 0.81 | BLM (0.48) | KDM4EKDM4CBLM | |
| SCHEMBL21012170 | 0.81 | BLM (0.48) | KDM4EKDM4CBLM | |
| SCHEMBL28126694 | 0.78 | BLM (0.47) | ZDHHC7ABCB1CA1CA2KDM4C | |
| SCHEMBL13640440 | 0.75 | CA1 (0.45) | ZDHHC7ABCB1CA1CA2KMT2A | |
| SCHEMBL9492420 | 0.75 | KDM4E (0.36) | KDM4EKMT2AATM | |
| SCHEMBL17670659 | 0.74 | ZDHHC7 (0.44) | L3MBTL1ZDHHC7ABCB1CA1CA2 | |
| SCHEMBL17371211 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376144-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TRANSLATE BIO, INC. | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376144-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POLB, SNRPB2, HNRNPA2B1 | L3MBTL1 456/4885ZDHHC7 2687/4885ABCB1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.